, Columnist
Clinton's New Drug-Price Attack
She's going after more than just the Martin Shkrelis of the world.
This article is for subscribers only.
After shaking the pharmaceutical industry earlier this year with a tweet, Hillary Clinton is back on the drug-price warpath.
She has previously focused on companies that price-gouge old, off-patent drugs, but her comments at a New Hampshire town hall on Tuesday should worry conventional drug makers as well. Clinton criticized a system in which a miraculous cure for Hepatitis C (HCV) can be cheap in Egypt but unaffordable in some U.S. states. The market reaction has been muted, especially compared to the swoon Clinton induced back in September. The Nasdaq Biotech Index, which fell 4.4 percent on the day of Clinton's fateful tweet, was down less than 1 percent on Wednesday. That reaction may turn out to be too mild.